Filtered By:
Drug: Insulin
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 51052 results found since Jan 2013.
A new angle for glp-1 receptor agonist: the medical economics argument Editorial on: Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015: 1-13 Epub ahead of print.
Authors: Valencia WM, Florez HJ
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are relatively new medications for diabetes that offer a weight-loss profile that can be considered desirable for patients with both type 2 diabetes (T2D) and obesity. GLP-1 RA are effective in combination with insulin, and even slightly superior or at least equal to short-acting insulin in T2D; however, since they work in the incretin system, they may not be effective in long-standing disease. Additionally, only recently have publications reported their cardiovascular safety, and there is limited evidence for long-term ef...
Source: Journal of Medical Economics - February 13, 2016 Category: Health Management Tags: J Med Econ Source Type: research
Factors complicating the diabetes management of visitors to Japan: advices from a Japanese National Center for overseas medical staff.
This article presents an instructive case and identifies various factors that can help in effective diabetes management of such cases. A Russian female patient aged 23 came to Japan and visited our hospital for a second opinion regarding glycemic control. She was diagnosed with type 1 diabetes at age three and started insulin injections and diet therapy with carbohydrate counting methods. Her HbA1c level was 11.0% with multiple daily insulin injections. She showed neuropathy, nephropathy, and blindness due to her progressed retinopathy. Because of the language barrier, suggestions for lifestyle modification were not effect...
Source: Journal of Medical Investigation - April 6, 2016 Category: Journals (General) Tags: J Med Invest Source Type: research
Diabetes Mellitus Treated with Medical Nutritional Therapy and Self Blood Glucose Monitoring: A Randomized Controlled Trial.
CONCLUSION: MNT combined with SBGM is an effective non-pharmacological intervention for patients with uncontrolled type 2 diabetes.
PMID: 27276835 [PubMed - in process]
Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet - June 11, 2016 Category: Journals (General) Tags: J Med Assoc Thai Source Type: research
Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.
CONCLUSIONS: EBID added to basal insulin was as effective in a real-world setting as mealtime insulin added to basal insulin in reducing A1C, with less weight gain and less hypoglycemia for a wide range of A1C attainment levels and baseline values.
PMID: 29394878 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 7, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Companion Medical launches data management system for smart insulin pen
Companion Medical launched today Insights by InPen, a diabetes management system that aggregates and analyzes data from Companion’s connected insulin injection pen.
The company’s Insights by InPen system provides users with their average glucose, average total daily insulin dose, dose calculator usage, missed doses and more, according to Companion Medical.
Get the full story at our sister site, Drug Delivery Business News.
The post Companion Medical launches data management system for smart insulin pen appeared first on MassDevice.
Source: Mass Device - June 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Companion Medical Source Type: news
Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump
Swiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump.
The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump appeared first on MassDevice.
Source: Mass Device - June 27, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Sanofi-Aventis Sensile Medical AG Verily Source Type: news
Companion Medical wins FDA nod for Android version of smart pen app
Companion Medical said today that it won FDA clearance for the Android version of its InPen app.
The company’s InPen system consists of a smart insulin injection pen that connects with an integrated diabetes management app. Companion Medical expects to release the app for Android users by the fourth quarter of this year.
Get the full story at our sister site, Drug Delivery Business News.
The post Companion Medical wins FDA nod for Android version of smart pen app appeared first on MassDevice.
Source: Mass Device - July 9, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Companion Medical Source Type: news
Surgical management of insulinomas at the Azerbaijan Medical University: a retrospective study of 21 cases over a 10-year period.
CONCLUSIONS: To prevent delayed diagnoses, physicians should be familiar with the typical symptoms of these rare tumors.
PMID: 32394681 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - May 14, 2020 Category: General Medicine Tags: Turk J Med Sci Source Type: research
Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis.
CONCLUSIONS: In the majority of unselected T2Dm patients admitted to our hospital, metabolic control was suboptimal. Implementation of treatment recommendations by both general practitioners and hospitals should be improved.
PMID: 24163110 [PubMed - in process]
Source: Swiss Medical Weekly - November 2, 2013 Category: Journals (General) Authors: Burgmann K, Fatio SA, Jordi B, Rutishauser J Tags: Swiss Med Wkly Source Type: research
Solutions For On-time, Deficient-Free Delivery Of Medical Supplies, Medicines And Other Products
For the person with diabetes in need of insulin, the heart patient awaiting a monitor or the individual expecting critical lab results, a delay of even one day isn't acceptable. Timely delivery of medical supplies or medication could mean the difference between recovery and relapse.
Source: Medical Design Online News - November 7, 2013 Category: Medical Equipment Source Type: news
Medical Human Insulin Market Is Expected to Reach $42 billion by 2019...
North America is the largest contributor to the global market while Asia is expected to grow at the highest rate....(PRWeb October 18, 2014)Read the full story at http://www.prweb.com/releases/medical-synthetic-insulin/market/prweb12250127.htm
Source: PRWeb: Medical Pharmaceuticals - October 19, 2014 Category: Pharmaceuticals Source Type: news
Companion Medical launches smart insulin pen in U.S.
Companion Medical started selling its smart insulin pen in the U.S. today, according to the San Diego, Calif.-based company.
The InPen system, which combines an insulin injector pen and a smartphone app, is compatible with Eli Lilly‘s (NYSE:LLY) Humalog and Novo Nordisk‘s (NYSE:NVO) Novolog fast-acting insulin.
Get the full story at our sister site, Drug Delivery Business News.
The post Companion Medical launches smart insulin pen in U.S. appeared first on MassDevice.
Source: Mass Device - December 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations mHealth (Mobile Health) Pharmaceuticals Companion Medical Eli Lilly & Co. Novo Nordisk Source Type: news
Companion Medical wins CE Mark for InPen insulin pen
Companion Medical said yesterday that it won CE Mark approval in the European Union for its InPen smart insulin pen and associated diabetes management smartphone application.
The company’s InPen system consists of a smart insulin injection pen that connects with an integrated diabetes management app.
Read the whole story on our sister site, Drug Delivery Business News
The post Companion Medical wins CE Mark for InPen insulin pen appeared first on MassDevice.
Source: Mass Device - July 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Diabetes Drug-Device Combinations Regulatory/Compliance Companion Medical Source Type: news
Bristol Medical School researcher awarded prestigious Diabetes UK fellowship
A Bristol Medical School researcher has been awarded a prestigious Diabetes UK fellowship to understand more about adult onset type 1 diabetes. It is estimated that more than 300,000 people in the UK are living with the disease which develops when the immune system makes a mistake and destroys the cells that make insulin.
Source: University of Bristol news - December 14, 2018 Category: Universities & Medical Training Tags: Health, Grants and Awards, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School Source Type: news
Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan
ConclusionAntidiabetic treatment has become complex in Taiwan. Although combination therapy would become the major treatment strategy gradually, the underuse of insulin therapy must improve.
Source: Journal of the Formosan Medical Association - June 25, 2019 Category: General Medicine Source Type: research
